Autonomic nervous system and sudden cardiac death  by Barron, H.V. & Lesh, M.D.
Z 
treatment of congestive heart failure post-Ml 
saves lives 
in NYHA class I-Ill patients. 
Reduces mortality 27%? 
40 lives saved per 1000 in the first year. ~~ 
Benefits een in both men and women. "~ 
Decreases progression tosevere/resistant 
heart failure 23%? 
Reduces hospitalization related to CHF 26%. ~ 
Available for mi.~g in water, apple juice 
and applesauce. 
As with all ACE inhibitors, the most commonly reported side effects 
include headache, fatigue, dizziness, dry cough, and angioedema (rare). 
Also, ACE inhibitors should be discontinued as soon as 
pregnancy is detected. 
Due to the risk of excessive hypotension associated with ACE inhibitor 
therapy, patients with congestive heart failure, with or without associated 
renal insufficiencv, should be monitored for the first 2 weeks whenever 
® 
A brief summary of the Prescribing Into rmution follows, 
USE IN PREGNANCY 
When used in pregnancy during the second left third trimesters. ACE i nblOders can cause ia~/and  even death to the devefop~ng 
ferns. When pregnancy is detected, ALTACE ~ should be flisconbnoed as soon as possible. See WARNINGS: Fetel/nemlatel me~idby 
end mmtrdly. 
INDICATIONS AND USAGE 
hly.m~ratnsfon: ALTAC E® (remip hi)is india ant d for the t re atTnent of bypo rtension. It may be used alone or in comblnapon with thiazrde 
diuretics 
in using ALTACE ~, consideration should be given to the fact that another augintenbln-conve riJn g enzyme [nhibitofi captopril, has caused 
ugranulocytosis" pardcubldy in pa~ents wrih renal impairment or cblfegemvast ular disease. Available data are insefi~cient to show that 
ALTADE ¢ does not have a similar risk. (See WARNINGS.) 
in eonsidedng use of ALTACE ~, h should be noted that in controlled trials ACE inhibifors have an effect en blood pressure that is less in black 
pa0ente than in non-blacks. In add ~on, ACE blhibitors (for which adequate data are available) cause a higher rate of angieedema in black 
than in non-bLack patients. (See WARNINGS,/Mgioedema.) 
Heart Fa/Alre post ~Kd ia l  ~ Ramigril is indicated in stable patients who have demonstrated clinical signs of congestive heart 
failure within the first few days a~er sustaining acute myocardial fefartbcn. Admidi~aden of ram/phi to such patients has been shown to 
decrease ~e risk of death (principally cardiovascular deathl and to decrease the risks of failure-related hospitalization and progression to 
sever e~resintant hoail f aiblre. 
~NDICAT IONG 
ALTACE ® is contraindicated i~ p adente who are hypersensr~ve to this product and in pobente with a hiatory of anginedema related to 
previous treatmect wi~ an angistensin-convening enzyme inblb0or. 
WARNINGS 
Ana/M)4acto/d and Po~/b~,Re/afed Reactfot~" Presumably because angiont~id-convertfeg enzyme inblbltors effect the metabolism of 
eicosancids and pblypeptides, including endogenous bradykksn, parents receiving ACE iofdbriors (including ALTACE ®) may be subject o a 
va daty of adverse reactions' some of them serious, 
A t~/~"  Pal,~ents with a history of augieedema unrelated to ACE inblbksr therapy may be at increased dsk of angioedema while 
receiving an ACE inblbito~ [See also CONI"RAJNDICATIONG.) 
Angioedema of the face, extremities, lips, tongue, glottis, and larynx has been reported in pohente treated w~ a ngiotensin-converdng 
enzyme idhibitors. Angioeriema associated wks laryngeal edema can be fatal. If laryngeal strider or angioefiema of the face, tongue, or 
gfet~s oc c u rs, treatment with ALTACE ® shonid be discondnueri and spprugnato therapy idshtnted immediately. Whoee thwe is involvement 
of the to~l~ue, gloths" or laqal~, likely to cause ath~ay Obsmlati~a ppopdate therapy, e.g., subcutaneous epinephnne so f~N 1 ~l~gO0 
103 mL m 0.5 mL) should be promplly ndeffnistwed. (See ADVERSE REACgONS.) 
In a large US postmarkebng study, angioedema (defined as repo~s of anglo, face, lazynx, tongue, or threat edema) was reported in 3/1,5~.3 
(0.20%~ of black pabento and in 8/8,680 (0.09%) of white patients. These rates were not different sma s'dcelly. 
ASth~flanteid reactiel~ during ldeserm~ee: Two patients undergoing desensr~zing treatment with h~llenoptera venom while 
receMng ACE inhibitors sustained lifeeffreamblug ana pbylantoid rea cbons. In the same padente, these reacbons were avoided when ACE 
inblb flare were temporarily withheld, but they reappeared u pen inadvertent rechbllenge. 
ASaphylautoiit reautfons daring membrane xposure: Aria phyla ctoid reacbons have been reported in pa0ents dialyzed w~ high-flux 
membranes and treated coneomitar~/with an ACE iefiibito~ Ansphytactoid reaclth~ have also been reported in p~ente undergnin? Iow- 
densby lipoprotein apberesis with dexl)'an sulfate absorption (a procedure dependent upo~ devices not approved in the United States/. 
Hype~nsi~v: ALTACE ® can cause symRtomade hypotensien, after either the inidel dose or a lamr dose when the dosage has been 
increased. Uke other ACE inhib~rs, ramigril has been only rare~y associated with bypntension in uncomplicated hypertensive pa~err=. 
SyInptemaric bypntension is most likely to occur in pobente who have been volume- andfor salt-depleted as a result of prolonged diurebc 
therapy, dietary salt resthcden, dialysis, diarrhea, or vomiting. Volume and/or salt depleoon should be corrected before ineia0ng therapy 
weft ALTACE ~. 
In patients with eenges~ve heart failure, with or without essocistod renal insLr~t iency, ACE inhibitor therapy may cause excessive 
hypctension, wblch tony be asseciated with oligufia or azotemia and, rarely, with at ute renbl failure and death In sued pat/ants' ALTACE = 
therapif should be started under close medical supervision;they should be followed closely for the first g weeks of treatment and whenever 
the dose of rekspdl or dblr~c k increased. 
If hypntensidn occurs, the padent should be placed in a supine position and, if necesstm/, treated with itmaveneus infusion of physiologic a[ 
saline. ALTACE ~ ~eatment usually can be conifoued following restoration of blood pressure and volume. 
Hepa~c Re/fern: Rarely, ACE inhibimrs have been associated with a syndrome that nta~ with ehblestoac aundice and progresses to 
fulminant hepatic necrosis and (somedmesl death. The mechanism of this syndrome is not understood. Radents receiving ACE inblidtors 
who develop jaundice or marked elevabcns of hpoabc enzymes should diseonifnue the ACE inhibitor and receive appropriate rnedioal 
folfew-up. 
~ en/a/'Agt anu/~y~ed~" Another angitsensin-converdng enzyme inhibitor, csptopfil, has been shown to cause agranulocytebls and 
bone marrow depression, rarely in uncomplicated pedants, but more frequently in pabents wdh renal impairment, especially if g%=y also 
have a collagen-vascular riisease such as systemic lupus e~hematesus or scleroderrna Available data from eliblc altrials of repspril are 
insufficient to show that ramipdi does not cause agrenulocytusis at similar rams. Monriohng of white blood cell counts should be 
considered in patients w~h collugen-vusc uiar disease, especially if the disease is associated with impaired renal function, 
F ~  ~ 7  and mef~l//y: ACE inhibitors can cause fetal and neonatal morbidity and death when administered to pregnant 
women. Several dozen cases have been reported in the world literature. When pregnanwis detected,ACE inblbitors should be 
discor~nued as soon as possible. 
The use of ACE inhibitors dutin9 the second and third trimesters of pregnancy has been associated with fetal and neonatal iniury, including 
bypntension, neonatal skull bypoplasia, anuha, reversible or irreversible renal failure, and death. 01igefiifdramblos has also been reported, 
presumably resu~ng from decreaseri fetal renal function; eligohydramblos in this setflnif has been associated with fntbl limb contraetures' 
craniofacial deferma~on, and hypuglesbc lung development. Prematurity, int~a uterine growth retardation, and patent ductos artoriosus 
have also been reported, a flhough it is not clear whether these oncunences were due to the ACE-inblbithr exposure. 
These adverse effects do not appear to have resulted from intrauterine ACE-blhiidtor exposure that has been }ira/ted m the first trinleater. 
Mothers whose em b~/us and fetuses are exposed m ACE inhib~tors only dudng the fl~l]imenter shoubl be so informed. None~eless, 
when patients become pregnant, physicians should make every effort m discontinue the use of ALTACE ® as seen as possible, 
Rarely (probably less often than ante in every thousand p~egnencins), no alternative to ACE inidbitors will be found, In rhese rare cases, tile 
mothers should be apprised of the patendel hazards to their fetuses, and serial uthasound examin~ons hould be pedormed te assess the 
intraamniefic en~ronment 
If elilgobydramblos is observed, ALTACE ~ should be discontinued unless if is considered IRe-saving for the mother Contraction s'eess te~ng 
(CST}, a non-stress test (NST), or biophysical profiling tBPP) may be appropriate, depending upon the week of pregnancy Rahonts and 
physicians should be aware, however, that eligefiythamnios may not appear untit after the fetus has sustained irreversible bliu ry. 
Infants with histories of in utero exposure to ACE inhibksrs should be closely observed far hyputension, oliguds' and hifperkafemia. If 
blignda occurs, a~ntion should tie directed toward support of blood pressure and renal perfusion. Exchange transfusion or dialysis may be 
required as means of reversing hypntension aeff/or substitubng for disordered renal fonc~o~ ALTACE ® which crosses the placenta oan be 
removed from the neonatal circelabon by these means, but limksd experience has not shown that such removal is central m the treatment 
of these infants. 
No terategenie effects of ALTACE ¢ were seen in stedies of pregnant rats, rabbi, and cyoomnigus monkeys. On a body surface area gas/s, 
the doses used were up to approximately 400 times (in rats and monkeys) and 2t~mes (in rabbits) the recommended human dose. 
PRECAUTIONS 
/m~bed ReeN F-u~-'~: AS a conseg uence of inblid'~ng the renin-angintensin-aldoaterone system, changes in renal fonc'don r~afl be 
antic/gated in susceptible individuals. In podents ~ severe congestive heart fa=ure whose renal fun~on may depend on the ac~vny of 
the renin-anifiotensin-aldosterone system, treatment wi~ angiatensbl-conve~ng enzyme inhibitors, includin0 ALTACE ®, may be assoeiantd 
wfth eliguria and/or progressive azotemia and (rarely) with aeute renal failure and/or death 
In hypertensive pa0ente vv~h unilateral or bilateral renal artery stenasis' increases in blood urea nitrogen and serum creadnine may occur. 
Expedenoe with another angiomnsin-conveding enzyme idfebdor ~ggeuts that these increases are usually reversible upon discor~nuafion 
of ALTACE ~ and/or diurebc therapy, fe such pedants renal funcbcn should be monitored during the first few weeks of therapy. Some 
hypertensive qadente with no apparent pre-existing renal vast blur disease have developed increases in blood urea nitrogen and serum 
creefinine, usually minor and transient, espenisily when ALTACE ~ has been given coneomitandy wrth a diuretic. This is more likely to oc t ur 
in pobccts widh pre-exis~ng renal impoirmenb Dosage redeefion of ALTACE* and/or discontinua~en of the diuredc mny tie reqnired. 
Evalaatine of the hypedens~e patient should always include assessmem of renal fonutfo~ (See DOSAGE AND ADMINISTRATION.} 
/~pentatemia: In clinical Vials, hypenielemia (serum potassium greater than ~7 mEq/LJ occunefl in spproxinlately 1% of hypertensive 
pa0ents receiving ALTACE ~. In most eases, these were isolated values' which resolved despite continued therapy. None of these p~ents 
was disconfin uefi from the abels tiecause of ifyporkalemia. Risk faaters for the development of hyperhalemia include renal blsofficiencif, 
diabetes mel~us' and the oonconflntnt use of pntassium-sporinif diuretics' potsssium supplements, and/or pntassium-containidg salt 
subs'dtates' which should be used ca~ously, if at all, with ALTACE'. (See DRUG INI1ERA~10NS.) 
Cough: Presumably due to the inhib~on of the dog rad abcn of endogenous bradykibln, qersistent nonproduc~ve cough has been reported 
all ACE inhibitors, a~ways resolving after discontinuation of therapy. ACE inhibi~r-ieduced cough should be considered in the 
differential diagnosis of cough. 
h~pa/red Liver Ftmct/ew: Since ramlptil is primarily metabolized by hepatic esterases to its ac0ve moiety, remiptilati patients w~ impaired 
liver function could develop markedly elevated plasma levels of ramipNNl. No formal pharmacokinetic studies have been carried out in 
hypertensive parents with impaired liver function. 
Sorgery/Anestbe,,~. In patients underifoblg surgery or during anesthesia with agents that produce h/f patens/on, ram/phi may block 
angiatensbl II formation that weeld otherwise occur secondary to compensatory renin release. Rifpomnsinn that occurs as a result of this 
mechanism can be oorrected byvolume expansion. 
k ~  for P ~  
Pr~mancy: Female patients of childbearing age should be told about the consequences of second- and third-~meuter exposure to ACE 
febibksrs" and they should also be told that these consequences de not appear m have resulted from intraLr~hoa ACE-inblbrior exposure 
that has been limited to the first trimeste~ These patients should be asked to report p~e(Jnancies m their physicians as ~ as possible. 
At~gfoedem~" Angieedems' including la~ngeel edema, can occur with tree,ant with ACE/rib/biters, especially fnilowing the first dose. 
Pader~ should be so advised and teid to report immediately any signs or symptoms suggesting anginefiema (swelling of fe re, eyes, lips, or 
tong ue, or drfficulty in bresthing) and to take no more drug unbl they have cer~ulted whh the prescifbidg physician. 
Sp~a~c ~ Patients should be caubonefi that ligfaheadefiness can occur, especially during the first days of therapy, and it 
shoutd be reported. Pa0ents should be mid that ff syncope occurs' ALTACE~ should be discontinued unblthe phpsician has been consulted. 
Ag patients should be c a~oned that inadequate fluid intake or excessive perspira~on, diarrhea, or vomidng can/sad to an excessive fall in 
blend pressure, with the same consequences of lightheaded heSS and possible syncope 
Hifperka,~m~: Patients should be told not to use sad supstriates containing qotossium without consulang their physician. 
Neueopema: Patients should be mid to prompify report any indication of infection (e.g., sore throat, fever}, which could be a sign of 
neutroflenla. 
Interactions 
~ i~ d/ure#c~" Padente on diurebcs, esgeciidly those in whom diuretic therapy was recenby ins~umd, may occasionally experience an 
excessive reduction of blood pressure aRar inifi~on of therapy with ALTACE ~. The possibility of hypctensive effects with ALTACE ~ can be 
minirsized by either diseo~nelugthe d[ureifc erincreasing the sat/intake prior to idigation oftreatmentwlthALTACE ~. Ifthisis nnt possible, 
the ntarbng dose should he reduced. (See DOSAGE AND ADMINISIRAT1ON.) 
W'~h po~ss/um supp/emente a~d p~a~l~m-spadng dtbred~" ALTACE ® c an attenuate potassium loss caused by thinzide d/urges. 
Pntassium-spadeg diuredes (spironolantone, amiidnde, Viamterene, and others) or potassium su pplemente can increase the risk of 
hyperkalemia. ~erefore, if concomitant use of such agents is indicated, they should be given wflh c auifon, and the patient's serum 
potassium should be monitored frequenW. 
I~hiu~ Increased serum li~ium levels and symptoms of I~ium toxicity have been reported in padents receiving ACE inhibriors dbong 
therapy with lithium. These drugs should be coadmiblstored wrth ca~on, and frequen: monitoring of serum litidum levels is recommended. 
If a diureac is also used, the risk of lithium toxicity may be increased 
OMec. Neither ALTACE ~ nor its metabofites have been found to interact with food, digoxin, antacid, forosemide, ckneddine, indomethaidn, 
and simvastetin. The combinapon of ALTACE ~ and propranclol showed no adverse effects on dynamic parameters)blood pressure and 
heart rate}, The ¢o-administraden of ALTACE ~ and warfarin did nat adversely effect the anthoeagelant effects of the latter drug. 
Addi0onally, co-administration of ALTACE = w~ phenproco umon did not affect mini~ urn phenprocoumon levels or ~torfare v~h the 
subiecte' state of an0-coagulation. 
Carcfooge~m~, J l&dag~/mpa/m~nt  of r-etl//~: No evidence of a tumorigenic effect was found when ramipnl was given by gavuge 
to rate for up m 24 months at doses of up to 500 mg/~/daif or to mice for up m 10 months at doses of up m 1,000 mg/k~gdey (For either 
species, these doses are about 200dines the maximum recommended human dose when oompsred on the basis of body surface area.) No 
rnatageblc aclJv~ was detected fe the Ames test in banteda, the micronucleus test in mice, unst heduled DNA synthesis in a human cell 
line, or a forward gene-mntefion assay in a Chinese hamster ovary cell Line. Several rnetobolites and deifradefi~ products of ramipril were 
also negaWe in the Ames test A study in rats with dosages as great as 5(X] mg/kg/dpy did not produce adverse effaeis on fardiW. 
Pmgnau~: Pregnanc~ Categories C (first rknester) and D/second and ~rd tomes~rs). (See WARNINGS: Felal/neonntal morbid fe/and 
rne~alby.) 
N~r~ 9 MoMet~ In/felon of single 10 mg oral dose of ALTACE ~ resulted in undetachable amounts of rarblpril and rts metabolitus in breast 
milk. However, because mul~ple doses may produce low milk eoncentr~ons that are nat predictable from sblgle doses, women reee~ug 
ALTACE ® should net breast feed. 
Gerfotdt U~¢ Of the total number of padente who received ramigril in US clinical studies of ALTACE ®, 11 ~)% were g5 and over whiin 0.2% 
were 75 and over. No overall differences in effecbveness or safety were observed batween these pobents and Younger pabents, and other 
reported clinical experience has not identified differences id responses between the elderly and younger parents, but greater sensilJvity of 
some older individuals cannot be ruled out_ 
One pharmacokine~c study conducted in hospitalized elderly patients indicated that peak ramiptilat levels and area under the plasma 
c oncentr~on time curve (AUD) for ramiprilat are higher in abler patients. 
Pediatric ~ Safety and effectiveness in pedia~c patients have not been established. 
ADVERSE REAC'nONS 
HReewen~e~" ALTACE ® has been evaluated for safety in over 4~)0 patients with hypertension; of these, 1,230 p~onte were studied in US 
c ontrellefi thals' and 1,107 were ntedied in foreign catto blleri viiss. Almost 700 of these podente were 'eeated for at leant 1 yee~ The overall 
incidence of reported adverse events was similar in ALTACE ~ and placebo pefier~. The most lrequent clinical side idfeets (possibly or 
probe bly related to study drug) reported by patients receiving ALTACE ® in US glaeebo-contrblled trials were: headache (5.4%1, "dizziness" 
(0.if%), and fadgue or asthenia (2.0%), bnt oblif the lant was more common fe ALTAC~ podente than in p~ente g/sen placeho. Denerally, the 
side effects were mild and transient, anti there was no reladen to total de,age within the range of 125 to 2Q mg. Discontinuation of therapy 
bet a use of a side effect was required in approximately 3% of US patients treamd with ALTACE*. The most common reasons for 
discondeuation were: cough (1.0%), "dizanuss" (0.5%). and impotence (0.4%). 
The side effects considered possibly or probably related to study drug that occurred in US placebo-contrblled ~ais in more than 1% of 
padects treated with ALTACE ~ are shown below. 
RATIENTS IN US PLACEB~LI .ED STUDIES 
ALTACE ~ Placebo 
N-~ N-~ 
n ~ ~ 
Headache 35 5.q 17 5.9 
"Dizziness" 14 g.2 9 3.1 
Anthobla (Fahgue) 13 2.0 2 0.7 
NauseaNomidug 7 1.1 3 1.0 
In placefio-contrblled trials, there was also an excess of upper respiratory iofeclfon and flu syndrome in the ramipbl group. As these studies 
were carried out before the relationship of cough m ACE idhifetors was recognized, some of these events may represent ramipdi-indu cod 
cough In a later 19ear atudif, iocreased cough was seen in almoat 12% of ramipril pedants' witJ~ abont 4% of these padents reduidng 
discon'dnu~on of treatment. 
HeanRaifotepeslnrfeca~ialir4arc~" Adverse reechoes (except laboratory abnormidides) considered possibly/probably related to 
study drug that occurred in more than I% of parents with heart failure treated ~ ALTACE ® are shown below. The incidences represent 
rhe exponences fTom the AIRE study The follow-ug 0me was between 6 and 46 months for this studif. 
Pmcemage of P~ente ~ Adverse Events Poss iMy~ly  Related to Stedy DnJ 0 
Placefio-Cont~ollefi (AIRE) Mortality Study 
Adverse Event RamipNNI Placebo 
( ~  - -~  
Hypotension 10.7 4.7 
Cough Increased 7.6 3.7 
Dizziness 4.1 3.2 
Angina Pectons 2.9 2,0 
Nausea 2.2 1.4 
Pontural Hyontensi~ 2.2 1.4 
Sytmopo 2.1 1.4 
Heart Failure g0 22 
Severe/Resistant Heart Failure 20 
My~cardiel Infarct 1.7 1.7 
Ve~Wng 1.6 &5 
Van/go 1 fl 0.7 
Headache 1.2 0~ 
Kidney Func~on 12 0.5 
Abnormal Chest Pain 11 0.9 
Diarrhea 11 0.4 
Anthenia 03 (18 
Other adverse expenen ces reported in controlled clinical trials (in less than 1% of ramigril pohonto), or rarer events seen in psStolarkeflng 
e~oerinnce, include the following (in some, a causal rel~onshig to drug use is uncertain): 
Body As a Whole: Ansp~actoid reacts .  {See WARNINGS) 
Cardiovuscube: Syrn pmmadc hypomnsion (reported in 0.5% of pobente in US thals) (See WARNINGS and PRECALmONG), syncope (not 
reported in US trinls), angina pectods' arthythmia, chest pain, palpitations, myocardial Jnfarcpon, and cerebrovascular events. 
Hematotegis: Pa ncytoponia, hemo4yde anemia, and thrombocytopenia. 
Raql: Some hype~nsive pabente with no apparent pre-exis~nif renal disease have developed minor, usually vansienL increases in bleed 
urea nitro/fen and serum crea0nine when taking ALTAC~, pa rticulariy when ALTACE® was given concomifatsly with a diurede. (See 
WARNINGS.) 
Angineurefi© Edema: Angioneur~e edema has been reported in 03.% of pbl~ents is US clinical the/s, (See WARNINGS) 
Cougk: A t/clUing, dry, porsisntpo nonproduclJve cough has been reported W~l the use of ACE inhibits. Approximately 1% of pshonts 
treated with ALTACE ~ have required discondeu~o~ because of cough. The cough disappears shortly alter disco~nuation of veatmena 
tSee PRECAUTIONS, Cough subsecbcn.) 
6ustminteatklal: Panerea~s, abdominal pain (sometimes WT~ enzyme changes suggesgng psncreet~s), anorexia, eonsiJpatfen, diarrhea, 
dry mouth, dyspepsia, dysphagia, gastmentor~s' hepo~s, nausea, increased salivaden, mate disturbance, and vomi~nif 
Oenna~legfe: Apparent hypersensitivity reac0ons (manifested by urbcboa, pruritus, or rash, with or without fever), erythema muififorrne, 
photosensblvity, and poqoure. 
NmJrofo@fe md Pm/chie~c: An.~ety, amnesia, convulsions, depression, healing loss, insomnia, nelvousness' neuralgia, neurepathy, 
poresthesis' somnolence, honitus' tremor, vardga, and vision disturbances. 
Misceffeneol~ AS w~ other ACE inhibksrs, a symptom complex has been reported which may include a posidve ANA, an elevated 
en/brecyto sedimentaaon ram, a~ralgiWarthri~, myblgia, fever, vasculiifs" eosinopbllin, photesensidvity, rash and other rierrnatologic 
manifestadens, 
FetelhleOnteof morbidily and mortality. )See WARNINGS: Fatal/aewaatal morbidity and rnostalie/.) 
Othe~ Arthralgia, arthritis, dyspnea, edema, epistaids, impotence, increased s~vea0ng, malaise, my'aloia, and weight gain. 
Clinical Lab~ Teat Red/eRe: 
Creatinfoe and Blood Urea Nilroge¢ blc teases in creatmine levels occurred in 12% of pogents receiving ALTACE ® alone, and in 1.5% of 
pogento receMng ALTACE e and a diureffc. Increases in blood urea nitrogen levels occurred in 05% of padente receiving ALTAC E ® alone and 
in 3% of parents receiving ALTACE ~ whh a diureac. None of these increases required disconl~uaden of Veatmen[ increases in these 
laboratory values are more likely to occur in pedants with renal insufflcinncy or those pretreated with a diuregc and, based on expetienee 
w~h other ACE idblbffors' would be expected to be especially likely in padects with renal artery stenosis. (See WAIHNGS and 
RRECALmONS.) Since ramigdl decreases eldeaterone secreden, efevabcn of serum potassium can nccun Potassium supplements and 
pntassium-spednif diurstJcs should be given with caution, and the pogent's serum potassium should be monitored frequency. (See 
WARNINGS and PRECAU11ONS.} 
Hmoglebin and Hematecvil: Decreases in he~noifinbin or hematocht (a low value and a decrease of 5 ~/dl or 5% respo~vely) were rare, 
occurring in 04% of patients rec~viug ALTAC E ~ alone and in 1.5% of patients reoeMng ALTACE ~ plus a diuregc No US patiento 
disconanued trea~ent because of decreases in hemoglobin er hematocfit 
(causal relefiushipo uefinnem~: Clinically important changes in standard laboratery tests were rare~y associated with ALTACE ¢ 
adminiatrabcn. Elevabcns of liver enzymes, serum bilirubin, udc acid, and blood glucose have been reported, as have cases of 
hyponaVehoa and scattered incidents of leukspebla, eosinughilis' and protblnoria. In US trials, less than 0.2% of pabents disc ondnued 
treatment fl)r laboraton/abr~malibcs: all of these were cases of proteineda or efincrmel liver-tone,on tests. 
OVERDOSAGE 
Single oral doses in rats and mice of 10-11 g~g resulted in signific ant lethality. In dogs, oral doses as high as 1 g./kg induced only milri 
pss~ni~es~nsi distress, Limited data on human overdosaif e are available. The most likely clinical manriestapons would be sym proms 
atthbcta bfe to hypntension. 
Laboratory determinations of serum levids of ramigdl and its metabolries are not w~dely avails ble, and such determin~ons have, in any 
event, no established rnie in the management of ramipril overdose. 
No data are avinla bdi to suggest physfelogical maneuvers (e.g,, maneuvers te chanife the pH of the ufine) that might aeebleram elimination 
of ramigrii and Its membolites. Similarly, it ix not known which, if any, of these substances can be usefelly removed from the body by 
hernedia~sis. 
Angiemnsin II could presumably serve as a specific antagonkt-an~deto 
in rhe setting of ramipril overdose, bat angiotensin II is essen~ally 
unavsilableoutsideofscefferedresearefifoell~es. Becausethehyps- Hoechst Marion Rou$$el 
nt~sble effect of ramipril is achieved through vasodilation and effective 
hypovblemis, it is reasonable to treat ramipdl overdose by fetus/on of 
normal saline solubon. Heaths, M~rlon Roundel. Inc" K~n~s C;ty. Me  ~4134-O527 
A member of ~he H~chst Group 
The Hoechst name and logo are registered trademarks of Hoechst AG. 
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Figure 1. Relation between heart rate variability and out- 
come in patients with varying degrees of left ventricular 
dysfunction. EF = ejection fraction; SDNN = standard 
deviation ofall normal RR intervals. Modified from Kleiger 
et al. (13). 
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Odemuyiwa et al. (15) assessed the utility of heart rate 
variability and left ventricular ejection fraction for predicting 
mortality after infarction as a function of follow-up duration. 
Heart rate variability and left ventricular ejection fraction were 
assessed in433 survivors of a first acute myocardial infarction. 
Both depressed heart rate variability and left ventricular 
ejection fraction <40% were strongly associated with total 
cardiac mortality (p < 0.0001), but reduced heart rate variabil- 
ity was an independent predictor of total cardiac mortality only 
during the first 6 months of follow-up. There were no deaths 
predicted by reduced heart rate variability after the first year of 
follow-up. Reduced heart rate variability was better than left 
ventricular ejection fraction <40% in predicting sudden deaths 
during the first year of follow-up but was an independent 
predictor only of those sudden deaths occurring within 6 
months of infarction. 
Baroreflex Sensitivity 
Baroreflex sensitivity is another method used to assess the 
autonomic nervous system tone. The arterial baroreceptor 
control of heart rate has been studied by three techniques: l)
Increasing blood pressure with a vasoconstricting a ent such as 
phenylephrine has been used to examine reflex parasympa- 
thetic tone. 2) Lowering blood pressure with a vasodilator such 
as nitroprusside has been used to examine reflex sympathetic 
tone. 3) Direct stimulation of the carotid baroreceptors with 
neck suction has also been used. The majority of studies that 
have examined the relation between the autonomic nervous 
system and sudden cardiac death have focused on reflex 
parasympathetic tone using the phenylephrine method. The 
most important studies are summarized herewith. 
Experimental data. The effect of myocardial infarction on 
baroreflex sensitivity was first studied in the conscious dog. 
Schwartz et al. (16) showed that baroreflex sensitivity was 
significantly lower in a group of 192 dogs 30 days after an 
anterior wall myocardial infarction than in a group of 86 
control dogs. Using their postmyocardial infarction dog model 
for inducing ventricular fibrillation with ischemia, Schwartz et 
al. (16) demonstrated that the baroreflex sensitMty was signif- 
icantly reduced in resistant dogs compared with dogs suscep- 
tible to ventricular fibrillation (9.1 vs. 17.7 ms/mm Hg, p < 
0.001). They demonstrated that the reduction in baroreflex 
sensitivity after myocardial infarction was of similar magnitude 
between resistant and susceptible dogs, implying that the 
difference between the two groups was present before the 
myocardial infarction occurred. 
Clinical studies. On the basis of these animal data, 
Schwartz et al. (17) examined baroreflex sensitivity after 
myocardial infarction in humans. They found that baroreflex 
sensitivity was lower in patients after a myocardial infarction 
than in control subjects (8.2 vs. 12.3 ms/mm Hg, p = 0.0001). 
Although there was considerable overlap between the two 
groups, 13 (41%) of the 32 patients had a baroreflex slope 
<6.5 ms/mm Hg, which was 2 SDs below the mean value of the 
control subjects. Over time, baroreflex sensitivity increased 
such that after 3 months, baroreflex sensitivity was similar to 
that in the control subjects (11.1 vs. 8.7 ms/mm Hg, p = 0.02). 
These findings supported the animal model data suggesting 
that baroreflex sensitivity is lower after myocardial infarction 
and that his reduction appears transient. The finding that both 
baroreflex sensitivity and heart rate variability (18) improve 
over time is particularly intriguing iven that the increased risk 
of sudden cardiac death after a myocardial infarction appears 
to decline over a similar time period (19). 
La Rovere et al. (20) performed the first clinical study to 
investigate the potential prognostic value of baroreflex sensi- 
tivity. They examined the relation between baroreflex sensitiv- 
ity and subsequent mortality in 78 patients <65 years old who 
experienced their first myocardial infarction. The baroreflex 
sensitivity of the entire cohort was 7.8 ms/ram Hg and was 
lower among patients with an inferior versus anterior myocar- 
dial infarction (6.1 vs. 8.9 ms/mm Hg, p = 0.03), with three- 
versus one-vessel disease (4.8 vs. 7.1 ms/mm Hg, p = 0.04), and 
with episodes of ventricular tachycardia (5.1 vs. 8.3 ms/mm Hg, 
p = 0.03). There was no correlation between baroreflex 
sensitivity and left ventricular ejection fraction or with mean 
pulmonary capillary wedge pressure at peak exercise. However, 
a correlation (r = 0.35, p < 0.001) was present with exercise 
tolerance. During the 2-year mean foUow-up eriod, there were 
six cardiovascular deaths (7.6%), four of which were sudden. 
Baroreflex sensitivity testing was markedly lower in the seven 
deceased patients than in the 71 survivors (2.4 vs. 8.2 ms/mm Hg, 
p = 0.004). A markedly reduced baroreflex sensitivity 
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Table 1. Correlation Among Baroreflex Sensitivity and Holter 
Electrocardiographic Measures of Heart Rate Variability 
BRS SDNN HFP pNN50 MSSD 
BRS 1.00 
SDNN 0.62 1.00 
HFP 0.63 0.55 1.00 
pNN50 0.58 0.55 0.94 1.00 
MSSD 0.57 0.56 0.94 0.97 1.00 
BRS = baroreflex sensitivity; HFP = high frequency power; MSSD = mean 
square successive difference; pNN50 = percent of difference between adjacent 
normal RR intervals that exceed 50 ms; SDNN = standard eviation of all 
normal RR intervals. Modified from Bigger et al. (22), with permission. 
Table 2. Comparison ofDifferent Prognostic Variables in Prediction 
of Arrhythmic Events 
Variable Sensitivity Specificity PPV (%) RR 
Late potentials 70 85 28 9.1 
Holter (>10 PVCs/h) 80 75 22 20.6 
LVEF <40% 80 77 23.5 10.4 
HRV (SDNN <50 ms) 60 94 55 10.4 
BRS (<3.0 ms/mm Hg) 80 91 44 23.1 
HRV = heart rate variability; LVEF = left ventricular ejection fraction; PPV = 
positive predictive value; PVCs = premature v ntricular complexes; RR = relative 
risk; other abbreviations as in Table 1. Modified from Farrell et al. (23), with 
permission. 
(-<3.0 ms/nun Hg) was associated with a 50% mortality rate 
compared with only 3% in those patients with a baroreflex 
sensitivity ->3.0 ms/ram Hg. The positive predictive value of a 
reduced baroreflex sensitivity for death was 50% (i.e., 5 of 10 
patients died when baroreflex sensitivity was -<3). 
Farrell et al. (21) studied the relation between autonomic 
tone and inducibility during programmed electrical stimula- 
tion. In those patients in whom sustained monomorphic ven- 
tricular tachycardia was induced, baroreflex sensitivity was 
significantly reduced (p = 0.001), as was heart rate variability 
(p = 0.007) and left ventricular ejection fraction (p = 0.022). 
The strongest association between any variable (including 
heart rate variability, baroreflex sensitivity, late potentials, left 
ventricular ejection fraction, exercise testing, Q waves and 
infarct site) and the induction of sustained monomorphic 
ventricular tachycardia was depressed baroreflex sensitivity, 
with a relative risk of 36 (95% confidence interval [CI] 5 to 
266). They also confirmed the finding that baroreflex sensitivity 
is inversely correlated with age but not with left ventricular 
ejection fraction. During the follow-up period, there were five 
adverse vents, all of which were correctly identified by de- 
pressed baroreflex sensitivity and programmed electrical stim- 
ulation. Baroreflex sensitivity was significantly depressed in 
these five patients compared with the remaining subjects (0.9 
vs. 7.4 ms/mm Hg, p = 0.002). Not only did they conclude that 
depressed baroreflex sensitivity identifies a subgroup at high 
risk for arrhythmic events after myocardial infarction, but that 
programmed electrical stimulation may be safely limited to this 
group without any loss of predictive accuracy. 
Several studies have examined the interrelation between 
heart rate variability and baroreflex sensitivity. Bigger et al. 
(22) found that baroreflex sensitivity had the strongest corre- 
lation with the percent of the successive RR intervals. How- 
ever, the correlation was only moderate (r = 0.63), indicating 
that heart rate variability did not accurately predict baroreflex 
sensitivity (Table 1). The fact that baroreflex sensitivity and 
heart rate variability are not redundant is consistent with the 
hypothesis that baroreflex sensitivity is a "vagal stress test," 
whereas heart rate variability measures the tonic vagal activity 
over a 24-h period (22). Given the observations made by 
Adamson et al. (11), it is possible that the change in heart rate 
variability with beta-blocker therapy is analogous to a heart 
rate variability stress test and might be more likely to correlate 
with baroreflex sensitivity. 
In 1992, Farrell et al. (23) reported the results of the largest 
prospective study comparing the clinical utility of various 
noninvasive markers of arrhythmic events, including heart rate 
variability, baroreflex sensitivity, signal averaged electrocardi- 
ography, left ventricular ejection fraction and Holter monitor- 
ing. They studied 122 patients 7 to 10 days after an acute 
myocardial infarction. During a 1-year follow-up period, there 
were 10 arrhythmic events. The sensitivity, specificity, positive 
predictive value and relative risk of these variables for predict- 
ing clinical events are summarized in Table 2. Depressed 
baroreflex sensitivity carried the highest relative risk for ar- 
rhythmic events (23.1, 95% CI 7.7 to 69.2) and was superior 
to other prognostic variables. It was significantly reduced in 
those patients who experienced an arrhythmic event (1.73 vs. 
7.83 ms/mm Hg, p = 0.0001) and sudden cardiac death (2.34 
vs. 7.54 ms/mm Hg, p = 0.0001). However, with respect to total 
cardiac mortality, baroreflex sensitivity was not significantly 
lower, as demonstrated in Figure 2. 
In a more recent study, Hohnloser et al. (24) also compared 
the potential predictive value of both heart rate variability and 
baroreflex sensitivity. Their study included 14 postinfarction 
patients who had experienced at least one episode of ventric- 
ular fibrillation or sustained ventricular tachycardia (Group 1) 
and 14 postinfarction patients without a tachyarrhythmic event 
after infarction (Group 2). Both groups were carefully matched 
with respect to age, gender, infarct location, extent of coronary 
artery disease, left ventricular ejection fraction, blood pressure 
and heart rate at rest. Indexes of heart rate variability were not 
significantly different between the two groups. However, 
baroreflex sensitivity showed a striking difference (Fig. 3). 
Group 1 patients had a mean value of 1.75 ms/turn Hg 
compared with 9.17 ms/ram Hg in Group 2 (p = 0.0002). 
Eleven of 14 Group 1 patients had a baroreflex sensitivity 
-<3.0 ms/mm Hg. By contrast, only 1 of 14 Group 2 patients 
had such a depressed value (Fig. 3). This study reiterates the 
differences in heart rate variability and baroreflex sensitivity 
and suggests that the latter, which measures the dynamic 
nature of the parasympathetic nervous system, may provide 
superior prognostic information. 
Many of the studies discussed here were carried out before 
the routine use of thrombolytic agents for acute myocardial 
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Figure 2. Relation between baroreflex sensitivity (BRS) 
and patients with (solid bars) and without (open bars) an 
event after myocardial nfarction. AE = arrhythmic event; 
SCD = sudden cardiac death. Modified from Farrell et al. 
(23), with permission. 
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infarction. To determine the effect of thrombolytic therapy on 
the evolution of baroreflex sensitivity after myocardial infarc- 
tion, Odemuyiwa et al. (25) assessed baroreflex sensitivity in 76 
patients, 53 of whom (70%) had received thrombolytic therapy. 
Mean age, sites of infarction and proportion of patients taking 
beta-blockers did not differ between patients who did and did 
not receive thrombolytic therapy. There was no difference in 
predischarge l ft ventricular ejection fraction (42% vs. 46%) 
between the two groups of patients, but baroreflex sensitivity 
was 9.2 ms/mm Hg in patients who received thrombolysis 
compared with 5.9 ms/mm Hg in those who did not (p = 0.03). 
This finding suggests that some of the beneficial effects pro- 
duced by thrombolytic therapy may result from preservation f 
the autonomic nnervation of the heart. 
Modulation of baroreflex sensitivity and outcome. Modu- 
lation of baroreflex sensitivity by drugs or other means might 
represent a novel approach to reducing the risk of sudden 
cardiac death in patients after a myocardial infarction. In 
animal studies, direct vagal nerve stimulation (26) as well as 
pharmacologic stimulation of the vagus nerve with carbacho- 
line, cyclic guanosine monophosphate (27), neostigmine (28), 
methacholine and oxtremorine (29) have been shown to re- 
duce the incidence of ventricular arrhythmias in an ischemic 
model of sudden cardiac death in dogs. The effect of various 
drugs on heart rate variability and baroreflex sensitivity have 
been tested in humans as well. 
Several investigators have examined the effects of low dose 
scopolamine, which at this dose has been shown to act as a 
muscarinic agonist. Dibner-Dunlap et al. (30) found that 
12 
10 
Figure 3. Significant difference in baroreflex sensitivity but 
not heart rate variability isseen in patients after a myocar- a 
dial infarction who developed a life-threatening ventricular 
tachyarrhythmia andcarefully matched postinfarction con- 6 
trol patients without any arrhythmic events, pNN50 = 
percent of difference b tween adjacent ormal RR intervals 
that exceed 50 ms; VF = ventricular fibrillation; VT = 4 
ventricular tachycardia; other abbreviations as in Figures 1 
and 2. Modified from Hohnloser tal. (24), with permission, z 
scopolamine increased vagal tone in 16 healthy oung men. 
Twenty-four hours after application of one scopolamine patch, 
the average RR interval was increased by 13%, and the average 
standard eviation of the RR interval was increased by 31%. 
Baroreflex sensitivity (as reflected by prolongation of RR 
interval provoked by graded neck suction) also increased 
substantially. These findings prompted De Ferrari et al. (31) to 
examine the effects of transdermal dministration f scopol- 
amine on heart rate variability and baroreceptor reflex sensi- 
tivity in 20 patients after myocardial infarction. Heart rate 
variability and baroreceptor reflex sensitivity were measured 
24 h after application of the scopolamine patch and were 
compared with the values measured before scopolamine and 
after application of a placebo patch. They demonstrated that 
scopolamine increased both heart rate variability and barore- 
ceptor reflex sensitivity significantly. The mean RR interval 
and its standard eviation increased by 7.1% (p -- 0.01) and 
25% (p = 0.004), respectively. The mean square successive 
difference increased by 38% (p = 0.0003) and the percent of 
intervals differing >50 ms from the preceding interval in- 
creased by 100% (p = 0.001). Baroreflex sensitivity increased 
by 42% (p = 0.0006). In a similar study, Vybiral et al. (32) also 
found that transdermal scopolamine caused a significant in- 
crease in heart rate variability. 
In addition to pharmacologic modulation, the autonomic 
nervous ystem can be influenced through daily exercise train- 
ing. Hull et al. (33) studied the effects of exercise on conscious 
dogs documented to be at high risk for the occurrence of 
ventricular fibrillation during acute myocardial ischemia. Dogs 
• Group 1 (VT/VF) 
[] Group Z (Control) p=0.002 
pnNS 
0.  
SDNNIIO(msec) pNN50 (96) BRS (maec/mm Hg) 
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were randomly assigned to 6 weeks of either daily exercise 
training or cage rest followed by exercise training. After 6 
weeks of daily treadmill training, heart rate variability in- 
creased by 74% (p < 0.001), and baroreflex sensitivity in- 
creased by 69% (p < 0.01). After exercise training, the 
incidence of ventricular fibrillation during acute myocardial 
ischemia decreased by 100% because all animals urvived. This 
was the first study to demonstrate hat by improving heart rate 
variability and baroreflex sensitivity, one could reduce the 
incidence of sudden cardiac death. These results suggested 
that exercise training in patients after a myocardial infarction 
may decrease their likelihood of developing lethal arrhythmias 
during acute myocardial ischemia. 
Seals et al. (34) studied healthy, previously sedentary men 
before and after either a period of regular endurance xercise 
or unchanged physical activity to determine the influence of 
physical training on cardiac parasympathetic tone. In general, 
heart rate variability was greater after training, suggesting that 
prolonged endurance training may increase cardiac vagal tone. 
Whether this data can be extrapolated to patients after a 
myocardial infarction is unknown. 
Mechanism of vagal protection. The mechanism by which 
vagal stimulation is protective against ventricular arrhythmias 
is unknown. Rosenshtraukh et al. (35) provided some insight 
into this issue by studying the mechanisms by which the 
muscarinic receptors act on the ventricle in vivo. They exam- 
ined the effects of vagal stimulation on ventricular repolariza- 
tion and on induction of lethal arrhythmias induced by 30 min 
of left anterior descending coronary artery ligation in anesthe- 
tized cats. The study divided the cats into four groups: normal 
control cats subjected to coronary ligation only, and cats 
pretreated with either atropine, pertussis toxin or propranolol. 
All cats were subjected to vagal stimulation. They found that 
stimulation of the vagus induced acceleration of ventricular 
repolarization in paced and unpaced hearts. The effect on 
repolarization was blocked by atropine and pertussis toxin but 
not by propranolol. The extent of sinus slowing and accelera- 
tion of repolarization was directly related to the level of 
functional pertussis toxin-sensitive G protein. Furthermore, 
the incidence of ventricular fibrillation was 10% in the control 
group and 50% and 54% in the atropine and pertussis toxin 
groups, respectively (p < 0.05). During atrial pacing before 
coronary occlusion, a vagal index was calculated as percent 
QTc shortening during ventricular stimulation. When the vagal 
index was 13% to 26%, the incidence of ventricular fibrillation 
during occlusion was zero. When the vagal index was 0% to 
12%, ventricular fibrillation was 52% (p < 0.01). 
Potential imitations of autonomic nervous system testing. 
Although assessment of autonomic activity has provided anew 
powerful method for risk stratification i patients after a myocar- 
dial infarction, heart rate variability and baroreflex sensitivity do 
have several limitations. First, heart rate variability and baroreflex 
sensitivity reflect he static and dynamic influence of the parasym- 
pathetic nervous ystem on the sinus node, respectively. Because 
vagal modulation of the sinus node is only a surrogate marker for 
its effect on the ventricle, these tests have the potential to 
misrepresent the true autonomic hanges occurring in the left 
ventricle. Another potential problem with heart rate variability is 
that recent work has challenged the hypothesis that low frequency 
spectral power eflects ympathetic tone. This observation stems 
from the fact that low frequency power does not respond to a 
variety of stimuli n the way one would expect of a pure measure 
of sympathetic tone (36-41). 
The study by Hohnloser et al. (24) demonstrated another 
limitation of heart rate variability. In that study, postmyocar- 
dial infarction patients who developed a cardiac arrest, com- 
pared with carefully matched postinfarction patients who did 
not experience major arrhythmic episodes, differed strikingly 
in terms of baroreflex sensitivity but not in terms of heart rate 
variability. That study highlights the differences between heart 
rate variability and baroreflex sensitivity and suggests that 
abnormalities in reflex tone may be more predictive of future 
events than abnormalities in tonic tone. Hohnloser et al. put 
forth one possible hypothesis to explain this finding. Patients 
with coronary artery disease who experience myocardial isch- 
emia have an increase in sympathetic efferent activity. This 
increase in sympathetic tone can be arrhythmogenic, especially 
if not accompanied by a reflex increase in vagal tone. Thus, 
patients' tonic vagal tone, as measured by heart rate variability, 
may be normal but their ability to respond to a stressor may be 
severely impaired; hence, they may succumb to sudden cardiac 
death. 
Finally, a recent study by Hull et al. (42) has questioned 
whether improving heart rate variability actually provides any 
protective advantage. In their dog model of sudden death, they 
tested the effect of low dose scopolamine in dogs that were 
found to be at high risk for developing sudden death. They 
found that scopolamine increased the standard eviation of 
RR intervals by 41%, increased the high frequency band of 
spectral analysis by 48% and decreased rest heart rate by 14%. 
Despite this increase in markers of vagal activity, ventricular 
fibrillation recurred in six dogs (86%). Thus, unlike exercise, 
which has been shown to improve both markers of vagal tone 
and prognosis, scopolamine appears to improve heart rate 
variability without providing any protection from sudden 
death. These data suggest that the method by which vagal tone 
is improved may be very important and that an intervention 
that improves autonomic tone may not provide an antifibrilla- 
tory effect. 
Conc lus ions  
There is compelling evidence linking sudden cardiac death 
and ventricular arrhythmias to the autonomic nervous ystem. 
Increased sympathetic activity appears to be proarrhythmic, 
whereas beta-blocker therapy and enhanced parasympathetic 
tone counteract this arrhythmogenic insult. Abnormalities in 
baseline parasympathetic one (heart rate variability) and in 
the ability to reflexively activate vagal tone (baroreflex sensi- 
tivity), leave patients after a myocardial infarction at high risk 
for developing ventricular taehycardia nd sudden cardiac 
death. Identifying such patients could be useful in clinical 
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decision making. Both heart rate variability and baroreflex 
sensitivity are noninvasive tests and are relatively inexpensive. 
Because heart rate variability requires only Holter monitoring 
equipment and appropriate software, it may be more feasible 
in many institutions. However, baroreflex sensitivity appears to 
be more predictive of future cardiac events. The Autonomic 
Tone and Reflexes After Myocardial Infarction Study is a 
multicenter prospective study in which 1,200 patients who have 
had a myocardial infarction will undergo a battery of noninva- 
sive tests, including assessment of left ventricular ejection 
fraction, signal-averaged electrocardiography, Holter monitor- 
ing, heart rate variability and baroreflex sensitivity testing. This 
study will add significantly to our understanding of how 
effective each test is in assessing future cardiovascular risk. 
Furthermore, ongoing research should elucidate the mecha- 
nisms by which increased vagal tone is protective, and this 
might lead to novel approaches to the treatment of ventricular 
arrhythmias and sudden cardiac death. 
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